Overview

Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes

Status:
Active, not recruiting

Trial end date:
2023-02-19

Target enrollment:

Participant gender:

Summary

An exploratory comparison of changes in liver fibrosis through glycemic control within and between groups after administration of Pioglitazone and Evogliptin in chronic hepatitis B patients with type 2 diabetes and liver fibrosis

Phase:

Phase 4

Details

Lead Sponsor:

Seung Up Kim

Treatments:

Pioglitazone